Clinical Trials Browser

von Hippel-Lindau Disease × belzutifan × 90 days × Clear all

NCT04924075 2026-02-24

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07405164 2026-02-12

MK-6482-043

Phase 3 Not yet recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease